The higher the decrease in the standardized uptake value of positron emission tomography after chemoradiation, the better the survival of patients with gastroesophageal adenocarcinoma
Open Access
- 3 November 2009
- Vol. 115 (22) , 5184-5192
- https://doi.org/10.1002/cncr.24604
Abstract
BACKGROUND: Postchemoradiation percentage decrease in standardized uptake value (SUV) of positron emission tomography (PET) from baseline correlates with overall survival (OS) and pathologic response. Analyses of dichotomized data are commonly reported. The authors analyzed percentage SUV decrease as both dichotomized and continuous variables.METHODS: The authors assessed 151 consecutive patients with gastroesophageal adenocarcinoma who had chemoradiation and surgery. Baseline and postchemoradiation PET/computed tomography imaging was performed. The log‐rank test and Cox proportional hazards models were used to associate percentage SUV changes and OS, and logistic regression models were used to detect the association between percentage SUV changes and pathologic response.RESULTS: A >52% SUV decrease (dichotomized analysis) was associated with a longer OS (log‐rank test,P= .023). The univariate Cox proportional hazards model indicated that greater percentage SUV decrease (as a continuous variable) was associated with a lower risk of death (hazard ratio [HR], 0.99;P= .01). Pathologic response (≤50% residual cancer) was associated with longer OS (P= .003). Patients with chemoradiation resistance (>50% residual cancer) tended to have a higher risk of death than those with chemoradiation sensitivity (0‐50% residual cancer; HR, 2.12;P= .099). In the multivariate model, the percentage SUV decrease (as a continuous variable) was the only prognosticator of OS (P= .01). The percentage SUV decrease was nonsignificantly associated with pathologic complete response (univariate odds ratio [OR], 1.01;P= .06 and multivariate OR, 1.03;P= .07).CONCLUSIONS: The greater the decline in SUV after chemoradiation, the longer is the OS of gastroesophageal adenocarcinoma patients. The percentage SUV decrease as a continuous variable is a better prognosticator of OS than its dichotomized assessments. Cancer 2009. © 2009 American Cancer Society.Keywords
This publication has 44 references indexed in Scilit:
- Genetic Variations in the PI3K/PTEN/AKT/mTOR Pathway Are Associated With Clinical Outcomes in Esophageal Cancer Patients Treated With ChemoradiotherapyJournal of Clinical Oncology, 2009
- Phase II Randomized Trial of Two Nonoperative Regimens of Induction Chemotherapy Followed by Chemoradiation in Patients With Localized Carcinoma of the Esophagus: RTOG 0113Journal of Clinical Oncology, 2008
- Incidence of Adenocarcinoma of the Esophagus Among White Americans by Sex, Stage, and AgeJNCI Journal of the National Cancer Institute, 2008
- Are Patients with Esophageal Cancer Who Become PET Negative after Neoadjuvant Chemoradiation Free of Cancer?Journal of the American College of Surgeons, 2008
- Imaging in the era of molecular oncologyNature, 2008
- Translating insights from the cancer genome into clinical practiceNature, 2008
- American Joint Committee on Cancer Staging System Does Not Accurately Predict Survival in Patients Receiving Multimodality Therapy for Esophageal AdenocarcinomaJournal of Clinical Oncology, 2007
- Value of baseline positron emission tomography for predicting overall survival in patient with nonmetastatic esophageal or gastroesophageal junction carcinomaCancer, 2005
- Dissecting the metastatic cascadeNature Reviews Cancer, 2004
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958